tetano
Editor, Senior Moderator
Vaccine. 2015 Apr 10. pii: S0264-410X(15)00359-X. doi: 10.1016/j.vaccine.2015.03.051. [Epub ahead of print]
[h=1]Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the last four seasons 2010-2014.[/h] Jim?nez-Jorge S[SUP]1[/SUP], Pozo F[SUP]2[/SUP], Larrauri A[SUP]3[/SUP], de Mateo S[SUP]4[/SUP], Delgado-Sanz C[SUP]5[/SUP], Casas I[SUP]6[/SUP], Garc?a-Cenoz M[SUP]7[/SUP], Castilla J[SUP]8[/SUP], Rodr?guez C[SUP]9[/SUP], Vega T[SUP]10[/SUP], Qui?ones C[SUP]11[/SUP], Mart?nez E[SUP]12[/SUP], Vanrell JM[SUP]13[/SUP], Gim?nez J[SUP]14[/SUP], Castrillejo D[SUP]15[/SUP], Altz?bar JM[SUP]16[/SUP], Gonz?lez-Carril F[SUP]17[/SUP], Ramos JM[SUP]18[/SUP], Serrano MC[SUP]19[/SUP], Mart?nez A[SUP]20[/SUP], Torner N[SUP]21[/SUP], P?rez E[SUP]22[/SUP], Gallardo V[SUP]23[/SUP]; cycEVA Study Team.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.
[h=4]METHODS:[/h] We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.
[h=4]RESULTS:[/h] In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).
[h=4]CONCLUSION:[/h] In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Case-control studies; Influenza; Interim analysis; Sentinel networks; Vaccine effectiveness
PMID: 25869892 [PubMed - as supplied by publisher]
[h=1]Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the last four seasons 2010-2014.[/h] Jim?nez-Jorge S[SUP]1[/SUP], Pozo F[SUP]2[/SUP], Larrauri A[SUP]3[/SUP], de Mateo S[SUP]4[/SUP], Delgado-Sanz C[SUP]5[/SUP], Casas I[SUP]6[/SUP], Garc?a-Cenoz M[SUP]7[/SUP], Castilla J[SUP]8[/SUP], Rodr?guez C[SUP]9[/SUP], Vega T[SUP]10[/SUP], Qui?ones C[SUP]11[/SUP], Mart?nez E[SUP]12[/SUP], Vanrell JM[SUP]13[/SUP], Gim?nez J[SUP]14[/SUP], Castrillejo D[SUP]15[/SUP], Altz?bar JM[SUP]16[/SUP], Gonz?lez-Carril F[SUP]17[/SUP], Ramos JM[SUP]18[/SUP], Serrano MC[SUP]19[/SUP], Mart?nez A[SUP]20[/SUP], Torner N[SUP]21[/SUP], P?rez E[SUP]22[/SUP], Gallardo V[SUP]23[/SUP]; cycEVA Study Team.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.
[h=4]METHODS:[/h] We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.
[h=4]RESULTS:[/h] In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).
[h=4]CONCLUSION:[/h] In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Case-control studies; Influenza; Interim analysis; Sentinel networks; Vaccine effectiveness
PMID: 25869892 [PubMed - as supplied by publisher]